



PRESS RELEASE

01 April 2025 08:40:00 CEST

New number of shares and votes in Senzime AB (publ)

The number of shares and votes in Senzime has increased during the month of March due to the directed issue of shares resolved by the board on February 26, 2025, as authorized by the general meeting on May 16, 2024.

As of March 31, 2025, the total number of shares in Senzime amounts to 133,215,046 (previously 133,174,523 shares), with one vote each. The share capital amounts to SEK 16,651,880.75 (previously SEK 16,646,815.375).

As of March 31, 2025, Senzime holds no treasury shares.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany.

Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at [senzime.com](https://www.senzime.com).

This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-04-01 08:40 CEST.

Attachments

[New number of shares and votes in Senzime AB \(publ\)](#)